The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men. West of Scotland Coronary Prevention Study

Journal of the American College of Cardiology

Volumn 33, Issue 4, 1999, Pages 909-915

  Sheperd, James ^a   Cobbe, Stuart M ^a,h   Ross, Lorimer A ^a   McKillop, James H ^a   Ford, Ian ^a   Packard, Christoper J ^a   Macfarlane, Peter W ^a,h   Isles, Christopher ^a   Oliver, Micheal F ^b   Lever, Anthony F ^c   Brown, Byron W ^d   Ledingham, John G G ^e   Pocock, Stuart J ^f   Rifkind, Basil M ^g   Vallance, Barry D ^h   Lorimer, Ross A ⁱ   MsKillop, James H ⁱ   Ballantyne, David ⁱ   Norrie, John ^a   Anderson, Liz ^a   Duncan, David ^a   Kean, Sharon ^a   Lawrence, Audrey ^a   McGrath, June ^a   Monthgomery, Vivette ^a   Percy, Melvyn ^j   Pomphrey, Elspeth ^a   Whitehouse, Andrew ^a   Cameron, Patricia ^a   Parker, Pamela ^a   Porteous, Fiona ^a   Flecher, Leslie ^a   Kilday, Christine ^a   Shoat, David ^a   Larif, Shahid ^a   Kennedy, Julie ^a   Bell, Margaret Anne ^a   Birell, Robert ^a   Mellies, Margot ^k   Meyer, Joseph ^k   Campbell, Wendy ^k   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d STANFORD UNIVERSITY   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h HAIRMYRES HOSPITAL   (United Kingdom)

ⁱ VICTORIA INFIRMARY   (United Kingdom)

^j Minerva Medical   (United Kingdom)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PATIENT ADMISSION; PRAVASTATIN; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SCOTLAND;

EID: 0033558686     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00657-3     Document Type: Article

References (17)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
2. Oliver M.F. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet. 337:1991;1529-1531.
3. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J. 304:1992;431-434.
4. Hulley S.B., Walsh J.M.B., Newman T.B. Health policy on blood cholesterol time to change directions . Circulation. 86:1992;1026-1029.
5. Muldoon M.F., Roussouw J.E., Manuck S.B., Glueck C.J., Kaplan J.R., Kaufmann P.G. Low or lowered cholesterol and the risk of death from suicide or trauma. Metabolism. 42:(Suppl 1):1993;45-56.
6. The Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
7. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
8. West of Scotland Coronary Prevention Study Group . A coronary primary prevention study of Scottish men aged 45-64 trial design . J Clin Epidemiol. 45:1992;849-860.
9. West of Scotland Coronary Prevention Study Group . Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol. 76:1995;485-491.
10. Kendrick S., Clarke J. The Scottish Record Linkage System. Health Bull (Edinb). 51:1993;72-79.
11. West of Scotland Coronary Prevention Study Group . Computerised record linkage compared with traditional follow-up methods in clinical trials and illustrated in a prospective epidemiological study . J Clin Epidemiol. 48:1995;1441-1452.
12. West of Scotland Coronary Prevention Study Group . Compliance and adverse event withdrawal their impact on the West of Scotland Coronary Prevention Study . Eur Heart J. 18:1997;1718-1724.
13. West of Scotland Coronary Prevention Study Group . Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 79:1997;756-762.
14. Tazuma S., Hatsushika S., Aihara N., et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion. 51:1992;179-184.
15. Smit J.W., van Erpecum E.J., Stolk M.F., et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology. 103:1992;1068-1070.
16. Pedersen T.R., Kjekshus J., Berg K., et al. Cholesterol lowering and the use of healthcare resources results of the Scandinavian Simvastatin Survival Study . Circulation. 93:1996;1796-1802.
17. Caro J., Klittich W., McGuire A., et al. The West of Scotland Coronary Prevention Study economic benefit analysis of primary prevention with pravastatin . Br Med J. 315:1997;1577-1582.